Document:

EX-10.1

 Exhibit 10.1 

TERMINATION AGREEMENT 

This TERMINATION AGREEMENT (this “Termination Agreement”), is dated as of August 21, 2017 by and among (i) Alliance
HealthCare Services, Inc., a Delaware corporation (the “Company”), (ii) THAIHOT Investment Company Limited, a company incorporated under the laws of the Cayman Islands (“THAIHOT”) and (iii) Tahoe Investment
Group Co., Ltd., (formerly known as Fujian Thai Hot Investment Co., Ltd., “Tahoe”). Each of the Company, THAIHOT, and Tahoe is referred to herein as a “Party” and collectively as the “Parties”.
Capitalized terms used but not defined herein shall have the meanings ascribed thereto in the Standstill Agreement (as defined below). 

RECITAL 
 WHEREAS, the
Parties entered into that certain Governance, Voting and Standstill Agreement, dated as of March 29, 2016 (the “Standstill Agreement”); 

WHEREAS, Alliance Healthcare Services Merger Sub Limited, a Delaware corporation (the “Merger Sub”), has entered into an
agreement and plan of merger, dated April 10, 2017 (the “Merger Agreement”) with the Company, Tahoe, THAIHOT and THAIHOT Investment Company US Limited, a Delaware corporation, pursuant to which the Merger Sub will merge with
and into the Company, with the Company being the surviving corporation (the “Merger”); and 
 WHEREAS, the Parties,
being all parties to the Standstill Agreement, desire to terminate the Standstill Agreement in its entirety immediately following the Effective Time (as such term is defined in the Merger Agreement) of the Merger. 

NOW, THEREFORE, the Parties agree as follows: 

1.    Termination of the Standstill Agreement. Subject only to the occurrence of the Effective Time, the Parties
hereby agree that the Standstill Agreement shall be unconditionally and irrevocably terminated in its entirety and shall be of no further force or effect immediately following the Effective Time of the Merger (the “Termination”),
except for Article VII (Confidentiality) and Article VIII (Miscellaneous) of the Standstill Agreement, which shall survive the Termination (collectively, the “Surviving Provisions”). 

2.    Release. Each Party, on behalf of itself and its present and former parents, subsidiaries, affiliates,
officers, directors, shareholders, members, successors and assigns (collectively, the “Releasors”), hereby agrees to, upon the Termination, release, waive and forever discharge each of the other Parties and their respective present
and former parents, subsidiaries, affiliates, employees, officers, directors, shareholders, members, agents, representatives, successors and assigns (collectively, the “Releasees”) of and from any and all actions, causes of action,
suits, losses, liabilities, damages, rights, obligations, costs, expenses, claims, and demands, of every kind and nature whatsoever, whether now known or unknown, foreseen or unforeseen, matured or unmatured (collectively, “Claims”)
which any of the Releasors ever had, now have, or may have against any of the Releasees by reason of any matter, cause, or thing whatsoever arising out of, based upon or relating to the Standstill Agreement

 
other than the obligations under the Surviving Provisions thereof. The foregoing release may be raised as a complete bar to any Claim against any of the Releasees by any of the Releasors, and the
Releasees may recover from any of the Releasors all costs incurred in connection with such Claim, including attorney’s fees. Each of the Releasees is irrevocably authorized to produce this Termination Agreement or a copy hereof to any
interested party in any proceeding with respect to the matters covered hereby. 
 3.    Governing Law;
Arbitration. This Termination Agreement shall be governed and construed in accordance with the internal laws (without reference to choice or conflict of laws) of the State of Delaware, and each Party hereby submits to the exclusive jurisdiction
and venue of the Delaware Court of Chancery of the State of Delaware, or, if the Delaware Court of Chancery is unavailable, any other court of the State of Delaware or, to the extent necessary, any federal court sitting in the State of Delaware.
Each Party hereby waives all right to a trial by jury in any action, suit or proceeding brought to enforce or defend any rights or remedies under this Termination Agreement. Each Party irrevocably consents to the service of any and all process in
any such action, suit or proceeding by the delivery of such process to such Party at the address and in the manner provided in Section 8.2. of the Standstill Agreement. 

4.    Counterparts; Entire Agreement. This Termination Agreement may be executed in one or more counterparts, each
of which shall be deemed to constitute an original, but all of which together shall constitute one and the same document. This Termination Agreement sets forth the entire agreement and understanding among the Parties with respect to the subject
matter hereof and supersedes all prior agreements, discussions or documents relating thereto. 

5.    Successors. This Termination Agreement shall inure to the benefit of, and be binding upon, the Parties and
their respective successors and assigns. 
 [Remainder of Page Intentionally Left Blank] 

  
 2 

 IN WITNESS WHEREOF, the Parties have caused this Termination Agreement to be executed and
delivered as of the date first written above. 
  

			
	Alliance HealthCare Services, Inc.
		
	By:	 	 /s/ Percy C. Tomlinson

	Name:	 	Percy C. Tomlinson
	Title:	 	Chief Executive Officer
	
	THAIHOT Investment Company Limited
		
	By:	 	 /s/ Qisen Huang

	Name:	 	Qisen Huang
	Title:	 	Director
	
	Tahoe Investment Group Co., Ltd.
		
	By:	 	 /s/ Qisen Huang

	Name:	 	Qisen Huang
	Title:	 	Director

 [Signature Page to the Termination Agreement]Adamis Pharmaceuticals Corporation 8-K

 

Exhibit 10.1

 

August 18, 2017

 

[Name]

[Address]

 

 

 

	 	RE:	Reset Offer of Common Stock Purchase Warrants

 

To Whom It May Concern:

Adamis Pharmaceuticals
Corporation (the “Company”) is pleased to offer to you the opportunity to reprice the exercise of all of the
Common Stock purchase warrants set forth on Annex I attached hereto (the “Reprice Warrants”) currently
held by you (the “Holder”). Certain of the Reprice Warrants (the “2014 Reprice Warrants”)
were issued pursuant to the Purchase Agreement dated as of August 19, 2014 (the “2014 Agreement”),
and certain of the Reprice Warrants (the “2016 Reprice Warrants”) were issued pursuant to the Purchase
Agreement dated July 11, 2016 (the “2016 Agreement” and together with the 2014 Agreement, the
“Purchase Agreements”), entered into by and among the Company and the signatories thereto. The resale of the
shares acquired upon exercise of the Reprice Warrants (“Warrant Shares”) has been registered pursuant to a registration
statement on Form S-3 (File No. 333-199454), and a registration statement on Form S-3 (File No. 333-212880) (collectively,
the “Registration Statements”). The Registration Statements are currently effective and, upon exercise of the
Reprice Warrants pursuant to this letter agreement, will be effective for the resale of the Warrant Shares. Capitalized terms not
otherwise defined herein shall have the meanings set forth in the 2014 Agreement or the 2016 Agreement (as applicable).

In consideration
for exercising in full all of the Reprice Warrants held by you (the “Warrant Exercise”), the Company hereby
offers you a reduced exercise price of the 2014 Reprice Warrants to $3.20, and a reduced exercise price of the 2016 Reprice
Warrants to $2.70 per share. Notwithstanding anything herein to the contrary, in the event that the Warrant Exercise would otherwise
cause the Holder to exceed the beneficial ownership limitations (“Beneficial Ownership Limitation”) in the Reprice
Warrants, the Company shall only issue such number of Warrant Shares to the Holder (as instructed in writing by Holder) that would
not cause such Holder to exceed the maximum number of Warrant Shares permitted thereunder with the balance to be held in abeyance
until the balance (or portion thereof) may be issued in compliance with such limitations. Holder shall provide written notice to
the Company promptly when any additional Warrant Shares may be issued in compliance with the Beneficial Ownership Limitation. The
balance of the Warrant Shares shall promptly be issued when Holder provides notice that Holder holds less than the Beneficial Ownership
Limitation.

Expressly subject
to the paragraph immediately following this paragraph below, Holder may accept this offer by signing this letter below, with such
acceptance constituting Holder’s exercise in full of the Reprice Warrants for an aggregate exercise price as set forth on
the Holder’s signature page hereto (the “Warrants Exercise Price”) on or before 8:00 a.m. (New York City
time) on August 21, 2017.

Additionally, the
Company agrees to the representations, warranties and covenants set forth on Annex A attached hereto.

From the date hereof
until five Trading Days after the date hereof (“Standstill Period”), neither the Company nor any Subsidiary
shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common
Stock Equivalents; provided, however, that this prohibition shall not apply to the Company’s issuance of securities upon
the exercise or exchange of or conversion of any securities exercisable or exchangeable for or convertible into shares of Common
Stock, or other similar rights, issued and outstanding on the date of this letter agreement, provided that such outstanding securities
have not been amended since the date of this letter agreement to increase the number of such securities or to decrease the exercise
price, exchange price or conversion price of such securities (other than any amendment pursuant to an Other Warrant Exercise Agreement).
The Company agrees that it will not amend any issued and outstanding option or warrant during the Standstill Period other than
warrants issued under the Purchase Agreements.

    	 

    	 

    

 

[Name]

August 18, 2017

Page 2

 

 

If this offer is
accepted on or before 8:00 a.m. (New York City time) on August 21, 2017, then on or before 9:00 a.m. (New York City time)
on August 21, 2017, the Company shall file a Current Report on Form 8-K with the Securities and Exchange Commission disclosing
all material terms of the transactions contemplated hereunder. The Company shall also file prospectus supplements to the Registration
Statements disclosing the reduced exercise price of the Reprice Warrants within 48 hours. The Company represents, warrants and
covenants that, upon acceptance of this offer, the shares underlying the Reprice Warrants shall be issued as provided in the Purchase
Agreements and in the Reprice Warrants and all of the Warrant Shares shall be delivered electronically through the Depository Trust
Company within the time periods specified therein after the date the Company receives the Warrants Exercise Price for the exercised
Reprice Warrants (or, with respect to shares that would otherwise be in excess of the Beneficial Ownership Limitation, within two
business days of the date the Company is notified by Holder that its ownership is less than the Beneficial Ownership Limitation).
Holder agrees to comply with all applicable securities laws concerning any resale of the Warrant Shares. The terms of the Reprice
Warrants, including, but not limited to, the obligations to deliver the Warrant Shares, shall otherwise remain in effect as if
the acceptance of this offer were a formal Notice of Exercise (including, but not limited to, any liquidated damages and compensation
in the event of late delivery of the Warrant Shares).

The Company acknowledges
and agrees that the obligations of the Holders under this letter agreement are several and not joint with the obligations of any
other holder of warrants of the Company issued pursuant to the Purchase Agreements (each, an “Other Holder”)
under any other agreement related to the exercise of such warrants (“Other Warrant Exercise Agreement”), and
the Holder shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such Other
Warrant Exercise Agreement. Nothing contained in this letter agreement, and no action taken by the Holders pursuant hereto, shall
be deemed to constitute the Holders and the Other Holders as a partnership, an association, a joint venture or any other kind of
entity, or create a presumption that the Holders and the Other Holders are in any way acting in concert or as a group with respect
to such obligations or the transactions contemplated by this letter agreement and the Company acknowledges that the Holders and
the Other Holders are not acting in concert or as a group with respect to such obligations or the transactions contemplated by
this letter agreement or any Other Warrant Exercise Agreement. The Company and the Holders confirm that the Holders have independently
participated in the negotiation of the transactions contemplated hereby with the advice of its own counsel and advisors. The Holders
shall be entitled to independently protect and enforce their rights, including, without limitation, the rights arising out of this
letter agreement, and it shall not be necessary for any Other Holder to be joined as an additional party in any proceeding for
such purpose.

***************

[signature pages follow]

    	 

    	 

    

 

[Name]

August 18, 2017

Page 3

 

 

To accept this offer,
Holder must counter execute this letter agreement and return the fully executed agreement to the Company on or before 8:00 am (New
York City time) on August 21, 2017.

Please do not hesitate
to call me if you have any questions.

	 	Sincerely yours,
	 	 
	 	ADAMIS PHARMACEUTICALS CORPORATION
	 	 
	 	 
	 	 
	 	By:	 
	 	Name:	Dennis J. Carlo
	 	Title:	Chief Executive Officer

  

 

[Holder signature page follows]

    	 

    	 

    

 

[Name]

August 18, 2017

Page 4

 

 

Accepted and Agreed to:

	Name of Holder:  	 

 

	Signature of Authorized Signatory of Holder:  	 

 

	Name of Authorized Signatory:  	 

 

	Title of Authorized Signatory:  	 

 

	Repriced Warrant Shares:  	 

 

	Aggregate Exercise Price:  $	 

 

	Repriced Warrant Shares issued on date hereof:  	 

 

 

	DTC Instructions:  	 

 

 

 

[signature page to ADMP Letter Agreement] 

    	 

    	 

    

Annex A

Representations, Warranties and Covenants
of the Company. The Company hereby makes the following representations and warranties to the Holder:

(a)                
Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by this letter agreement and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby
have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company,
its board of directors or its stockholders in connection therewith. This letter agreement has been duly executed by the Company
and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable
against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally;
(ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies; and
(iii) insofar as indemnification and contribution provisions may be limited by applicable law.

(b)               
No Conflicts. The execution, delivery and performance of this letter agreement by the Company and the consummation
by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the
Company’s certificate of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute
a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any
lien or encumbrance upon any of the properties or assets of the Company in connection with, or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility,
debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company
is a party or by which any property or asset of the Company is bound or affected; or (iii) subject to such filings that may be
required pursuant to applicable federal or state securities laws or rules of any stock exchange on which the Common Stock is traded,
which the Company undertakes to file within the applicable time periods, conflict with or result in a violation of any law, rule,
regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company
is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is
bound or affected, except, in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to
result in a Material Adverse Effect (as defined in the Purchase Agreement). 

    	 

    	 

    

Annex I

Reprice Warrants

 

	Investor	Issue Date	Exercise Price	Warrant Shares

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}]]